Search Results for:

IBEC is to be part of a revolution in fetal surgery and the research of prenatal diseases thanks to support by the Obra Social ”la Caixa” and Cellex foundations.

The two foundations are set to fund two major projects coordinated by the Fetal Medicine Research Centre, Fetal i+D (Hospital Clínic and Hospital Sant Joan de Déu). A fetal surgery part of the project, promoted by the Cellex Foundation, will improve the interventions currently being carried out, as well as developing new surgery to treat problems that currently lack solutions.

The Spanish Nanomedicine Platform (NanomedSpain), led by IBEC director Josep Samitier, is once again participating in the annual conference of Spain’s Plataformas Tecnológicas de Investigación Biomédica.

At the meeting, which is being held at the Hotel Crowne Plaze today and tomorrow, the keynote speaker invited by NanoMed Spain is Sylvia Bove, CEO of EIT Health. In addition, the Platform is organizing a parallel session on innovation in nanomedicine, in which various projects funded by the European programme H2020 will be presented. These success stories will include IBEC’s Elena Martinez’s ERC Consolidator grant to use biomimetic systems to study intestinal epithelium related diseases, as well as the SME Neos Surgery, which has received funding to complete the development of a new device for spine surgery.

More than 250 companies and public organizations met at Thursday’s Nit de CataloniaBio 2016, the annual forum for the sector, which this year had a special focus on the 10th anniversary of organiser CataloniaBio.

CataloniaBio is an association of companies, but the most relevant public institutions and research centers were invited, and IBEC was represented by director Josep Samitier and Xavier Rúbies and Diana Gonzalez from the Technology Transfer unit.

Also present at the event was the conseller of Health, Antoni Comín, the conseller of Business and Knowledge, Jordi Baiget, CataloniaBio president and Reig Jofre CEO Ignasi Biosca, and CataloniaBio vice-president and Kern Pharma’s Director of Strategy and Development Clara Campàs.